Ezekiel J. Emanuel, M.D., is an oncologist, author, and a senior fellow at the Center for American Progress. He was founding chair of the Department of Bioethics at the National Institutes of Health. Previously, he served as a special advisor on health policy to the director of the Office of Management and Budget and National Economic Council. Emanuel is author of several books including Prescription for the Future and Reinventing American Health Care. He is currently Vice Provost for Global Initiatives at the University of Pennsylvania, a Venture Partner at Oak HC/FT, and a Fox News contributor.
More About Dr. Ezekiel J. Emanuel
Medicare is proposing to provide a flat fee to physicians for administering a drug regardless of its price along with a smaller percentage add-on payment. This would be good for consumers.
Drs. Emanuel and Campbell join Morning Joe to discuss prescription drug prices and who is to blame.
Drug prices are out of control. No one really disputes it, and the real question is: Do we have the political will to do anything about it?
You may not know it, but you could be on the hook to pay at least $124 this year for a drug you probably don’t take.
Republicans and Democrats need to put politics aside to tweak urgent problems, Dr. Ezekiel Emanuel says.
In an interview with Isaac Chotiner, Dr. Ezekiel J. Emanuel discussed his meetings with President Donald Trump about health care, how to make Obamacare better, and why this White House is unwilling or unable to make bipartisan policy.
As Senate Republicans craft their healthcare bill, the legacy of what did and didn’t work in the Affordable Care Act casts a long shadow over healthcare policy discussions.
Politicians frequently declaim that we need a health care system rather than a sick care system. They are right, and high touch medicine and bundled payments are the best ways to catalyze that change.
The Republicans’ health bill is an act of supreme hypocrisy and insensitivity to the experience of Americans. It will damage — not improve — the U.S. health system.
Given how much they benefit from the current system, it’s no surprise that the drug industry and some physician groups oppose Medicare’s proposal. They raise two objections. First, financial incentives don’t drive physician prescribing behavior and, second, patients will be denied the medicines they need.